Strategic Partnerships Seek advisory and governance collaboration with board members connected to biotech, consumer health, and aging research. Leaps by Bayer and related executives on the board suggest openness to strategic alliances and potential co-development ventures.

Investment Signals capitalize on their recent $12M Series A and ongoing funding momentum to propose sponsored research, pilot programs, or fee-for-service collaboration with larger health systems or biotech firms seeking inflammation biomarkers and personalized nutrition insights.

Clinical Validation Position the iAge test as a scalable biomarker platform for chronic inflammation monitoring in chronic disease management programs, offering integration with electronic health records and population health initiatives.

Enterprise Expansion Target health plans and employer systems that resemble listed market peers by highlighting potential cost savings through early inflammation risk stratification and preventive health interventions.

Technical Synergy Propose technology partnerships around AI-driven analytics, data interoperability, and secure site infrastructure to accelerate commercialization, improve data insights, and streamline regulatory-ready product deployment.